This is a demo store. No orders will be fulfilled.

Life Sciences

Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas

The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.

Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.

The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.

We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.

We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.

  1. This edition of the Drug Discovery TOE depicts the current landscape and the new life sciences trends across emerging business models in the biopharmaceutical industry. The corresponding patent scenario is depicted, along with the industry interactions.. The Drug Discovery TechVision Opportunity Engine (TOE) reports and analyzes about the latest ...

    $950.00
  2. This edition of the Genetic Technology TOE depicts the current landscape and the new life sciences trends across biotherapeutics and genomics. The corresponding patent scenario is depicted, along with the industry interactions. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emp...

    $250.00
  3. Frost & Sullivan reviews key themes and industry trends from the 5th Annual Digital Health Summer Summit and BIO International held in June 2016. Major topics covered include the use of virtual and augmented reality in medical education and clinical care; new digital health technologies to improve mental health; investor perspectives on the market ...

    $1,500.00
  4. After many years of basic research, regenerative medicine represents a remarkable foremost innovation in medical care. Comprising principles of stem cell technology and tissue engineering, also combining advanced biomaterials with small molecules and biologics, to replace or regenerate human tissues and organs and restore their functions, regenerat...

    $4,950.00
  5. This edition of the Genetic Technology TOE depicts a range of innovations that have been patented in the space of 3D bioprinters. The issue also focuses on some of the key patents that have been filed around the space of 3D bioprinting, related products and bioinks that are needed for the development of 3D tissue models. Insights have been provided...

    $250.00
  6. TechVision's latest edition of Inside R&D TOE features innovations across various industries and market segments. This edition profiles an innovative energy harvesting method that can generate energy from body fluids for domestic use and a biologically-active walls that help in indoor air purification, a solar-based distillation unit for oil extrac...

    $250.00
  7. 01 Jul 2016  |  Europe

    Western Europe Point-of-Care Testing (POCT) Market

    Point-of-care testing is an integral part of the IVD market that is rapidly evolving into a preferred testing mode in the EU region. POCT is a segment that presents growth opportunities for a cross-section of players, ranging from OEMs to data integrators to technology vendors. The stakeholders need to be abreast of the challenges posed by the indu...

    $4,950.00
  8. The market for regenerative medicine, one of the fastest growing segments in the biotechnology industry, is estimated to reach $67.5 billion by 2020 recording a compound annual growth rate (CAGR) of 22%. Current industry trends signal the expanding horizons of regenerative medicine, with its application being explored in new therapeutic segments su...

    $1,500.00
  9. 30 Jun 2016  |  Global

    Global Immunoglobulin Therapeutics Market

     

    Immunoglobulin (Ig) therapies are among the oldest therapeutic moieties employed in a broad range of pathological conditions. Immunoglobulin G (IgG) holds the highest share (44%) in the global blood plasma market, with a revenue of $9.24 billion. Currently, the global Ig market is dominated by three major companies, holding about 85% of the total m...

    $1,500.00
  10. This Vital Signs issue discusses Sinocare's acquisition of PTS Diagnostics, biosimilar drug pricing, Americans' usage of prescription pain killers, and Takara Bio's acquistion of Wafergen Bio-systems.

    $450.00